| 1 | Inflammatory Tongue Conditions and Risk of Oral Tongue Cancer Among the US Elderly Individuals | 14.2 | 13 | Citations (PDF) |
| 2 | Cancer screening with multicancer detection tests: A translational science review | 169.9 | 46 | Citations (PDF) |
| 3 | The Development and Performance of Alternative Criteria for Lung Cancer Screening | 8.9 | 7 | Citations (PDF) |
| 4 | Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening | 5.2 | 4 | Citations (PDF) |
| 5 | The American Cancer Society National Lung Cancer Roundtable strategic plan: Current challenges and future directions for shared decision making for lung cancer screening | 4.3 | 5 | Citations (PDF) |
| 6 | Study design considerations for trials to evaluate multicancer early detection assays for clinical utility | 5.2 | 41 | Citations (PDF) |
| 7 | Upper age-limits for US male HPV-vaccination for oropharyngeal cancer prevention: A microsimulation-based modeling study | 5.2 | 7 | Citations (PDF) |
| 8 | Efficient and robust propensity‐score‐based methods for population inference using epidemiologic cohorts | 2.1 | 9 | Citations (PDF) |
| 9 | A Quantitative Framework to Study Potential Benefits and Harms of Multi-Cancer Early Detection Testing | 0.9 | 16 | Citations (PDF) |
| 10 | Management of Lung Cancer Screening Results Based on Individual Prediction of Current and Future Lung Cancer Risks | 1.1 | 20 | Citations (PDF) |
| 11 | The Improving Risk Informed HPV Screening (IRIS) Study: Design and Baseline Characteristics | 0.9 | 6 | Citations (PDF) |
| 12 | Inaccuracies in electronic health records smoking data and a potential approach to address resulting underestimation in determining lung cancer screening eligibility | 4.1 | 68 | Citations (PDF) |
| 13 | Abstract PR-13: Potential effect on racial/ethnic disparities of removing racial/ethnic variables from risk models: The example of lung-cancer screening | 0.9 | 1 | Citations (PDF) |
| 14 | Inflammatory markers in women with reported benign gynecologic pathology: an analysis of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial | 1.7 | 5 | Citations (PDF) |
| 15 | Association of Antiparietal Cell and Anti-Intrinsic Factor Antibodies With Risk of Gastric Cancer | 8.6 | 30 | Citations (PDF) |
| 16 | Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial | 5.9 | 7 | Citations (PDF) |
| 17 | Using Prediction Models to Reduce Persistent Racial and Ethnic Disparities in the Draft 2020 USPSTF Lung Cancer Screening Guidelines | 5.2 | 107 | Citations (PDF) |
| 18 | Gastroesophageal reflux disease: A risk factor for laryngeal squamous cell carcinoma and esophageal squamous cell carcinoma in the NIH‐AARP Diet and Health Study cohort | 4.3 | 30 | Citations (PDF) |
| 19 | Risk-Based Selection of Individuals for Oral Cancer Screening | 14.2 | 41 | Citations (PDF) |
| 20 | A Simple Framework to Identify Optimal Cost-Effective Risk Thresholds for a Single Screen: Comparison to Decision Curve Analysis | 1.2 | 3 | Citations (PDF) |
| 21 | Aspirin, ibuprofen, and reduced risk of advanced colorectal adenoma incidence and recurrence and colorectal cancer in the PLCO Cancer Screening Trial | 4.3 | 22 | Citations (PDF) |
| 22 | Executive SummaryChest, 2021, 160, 1959-1980 | 0.5 | 14 | Citations (PDF) |
| 23 | Prognostic impact of pre-transplant chromosomal aberrations in peripheral blood of patients undergoing unrelated donor hematopoietic cell transplant for acute myeloid leukemia | 3.7 | 4 | Citations (PDF) |
| 24 | Screening for Lung CancerChest, 2021, 160, e427-e494 | 0.5 | 195 | Citations (PDF) |
| 25 | Population Attributable Risks of Subtypes of Esophageal and Gastric Cancers in the United States | 0.4 | 34 | Citations (PDF) |
| 26 | Pre-HCT mosaicism increases relapse risk and lowers survival in acute lymphoblastic leukemia patients post–unrelated HCT | 5.3 | 6 | Citations (PDF) |
| 27 | Predicting Lung Cancer Occurrence in Never-Smoking Females in Asia: TNSF-SQ, a Prediction Model | 0.9 | 45 | Citations (PDF) |
| 28 | Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting | 4.5 | 10 | Citations (PDF) |
| 29 | Basing Eligibility for Lung Cancer Screening on Individualized Risk Calculators Should Save More Lives, but Life Expectancy Matters | 5.2 | 12 | Citations (PDF) |
| 30 | Pre‐transplant short telomeres are associated with high mortality risk after unrelated donor haematopoietic cell transplant for severe aplastic anaemia | 2.5 | 14 | Citations (PDF) |
| 31 | Ischaemic heart disease and stroke mortality by specific coal type among non-smoking women with substantial indoor air pollution exposure in China | 5.2 | 30 | Citations (PDF) |
| 32 | Serum ghrelin and esophageal and gastric cancer in two cohorts in China | 4.5 | 24 | Citations (PDF) |
| 33 | Oral Leukoplakia and Risk of Progression to Oral Cancer: A Population-Based Cohort Study | 5.2 | 147 | Citations (PDF) |
| 34 | A Prospective Study of Circulating Chemokines and Angiogenesis Markers and Risk of Multiple Myeloma and Its Precursor | 3.2 | 15 | Citations (PDF) |
| 35 | Addressing Disparities in Lung Cancer Screening Eligibility and Healthcare Access. An Official American Thoracic Society Statement | 9.3 | 192 | Citations (PDF) |
| 36 | Number needed to test: quantifying risk stratification provided by diagnostic tests and risk predictions | 0.4 | 2 | Citations (PDF) |
| 37 | Response to Brandt, Bednarz-Knoll, Kleinheinz et al | 5.2 | 0 | Citations (PDF) |
| 38 | Statistical approaches using longitudinal biomarkers for disease early detection: A comparison of methodologies | 1.8 | 5 | Citations (PDF) |
| 39 | Association of donor IFNL4 genotype and non-relapse mortality after unrelated donor myeloablative haematopoietic stem-cell transplantation for acute leukaemia: a retrospective cohort study | 6.2 | 11 | Citations (PDF) |
| 40 | Improving External Validity of Epidemiologic Cohort Analyses: a Kernel Weighting Approach | 1.2 | 27 | Citations (PDF) |
| 41 | Sample‐weighted semiparametric estimation of cause‐specific cumulative risk and incidence using left‐ or interval‐censored data from electronic health records | 1.8 | 0 | Citations (PDF) |
| 42 | Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines | 2.0 | 189 | Citations (PDF) |
| 43 | Risk of Prostate Cancer–related Death Following a Low PSA Level in the PLCO Trial | 1.1 | 8 | Citations (PDF) |
| 44 | “I'm not a freshi”: Culture shock, puberty and growing up as British-Bangladeshi girls | 4.5 | 11 | Citations (PDF) |
| 45 | Assessing Endogenous and Exogenous Hormone Exposures and Breast Development in a Migrant Study of Bangladeshi and British Girls | 3.1 | 7 | Citations (PDF) |
| 46 | 2019 ASCCP Risk-Based Management Consensus Guidelines: Methods for Risk Estimation, Recommended Management, and Validation | 2.0 | 95 | Citations (PDF) |
| 47 | Development and validation of an individualized risk prediction model for oropharynx cancer in the US population | 4.3 | 27 | Citations (PDF) |
| 48 | Insights for Management of Ground-Glass Opacities From the National Lung Screening Trial | 1.1 | 21 | Citations (PDF) |
| 49 | Quantifying risk stratification provided by diagnostic tests and risk predictions: Comparison to AUC and decision curve analysis | 1.8 | 13 | Citations (PDF) |
| 50 | Prioritized concordance index for hierarchical survival outcomes | 1.8 | 9 | Citations (PDF) |
| 51 | A Pragmatic Testing-Eligibility Framework for Population Mutation Screening: The Example of <i>BRCA1/2</i> | 0.9 | 6 | Citations (PDF) |
| 52 | Circulating inflammation markers and colorectal adenoma risk | 3.0 | 18 | Citations (PDF) |
| 53 | Contemporary Implications of U.S. Preventive Services Task Force and Risk-Based Guidelines for Lung Cancer Screening Eligibility in the United States | 8.9 | 23 | Citations (PDF) |
| 54 | Life-Gained–Based Versus Risk-Based Selection of Smokers for Lung Cancer Screening | 8.9 | 101 | Citations (PDF) |
| 55 | Role of Screening History in Clinical Meaning and Optimal Management of Positive Cervical Screening Results | 5.2 | 23 | Citations (PDF) |
| 56 | Testing Positive on a Multigene Panel Does Not Suffice to Determine Disease Risks | 5.2 | 4 | Citations (PDF) |
| 57 | A novel metric that quantifies risk stratification for evaluating diagnostic tests: The example of evaluating cervical-cancer screening tests across populations | 2.9 | 11 | Citations (PDF) |
| 58 | Donor telomere length and causes of death after unrelated hematopoietic cell transplantation in patients with marrow failureBlood, 2018, 131, 2393-2398 | 1.0 | 25 | Citations (PDF) |
| 59 | Clinical Outcomes after Conservative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in Women Ages 21–39 Years | 1.1 | 33 | Citations (PDF) |
| 60 | Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening | 5.2 | 139 | Citations (PDF) |
| 61 | Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records | 2.9 | 17 | Citations (PDF) |
| 62 | Nonparametric Adjustment for Measurement Error in Time-to-Event Data: Application to Risk Prediction Models | 3.5 | 5 | Citations (PDF) |
| 63 | Is the Women’s Health Initiative (WHI) Dietary Modification Associated With a Reduced Risk of Pancreatic Cancer? | 5.2 | 1 | Citations (PDF) |
| 64 | Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer | 14.2 | 85 | Citations (PDF) |
| 65 | Preventing Lung Cancer Mortality by Computed Tomography Screening: The Effect of Risk-Based Versus U.S. Preventive Services Task Force Eligibility Criteria, 2005–2015 | 8.9 | 43 | Citations (PDF) |
| 66 | Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer | 8.9 | 65 | Citations (PDF) |
| 67 | Implications of Nine Risk Prediction Models for Selecting Ever-Smokers for Computed Tomography Lung Cancer Screening | 8.9 | 162 | Citations (PDF) |
| 68 | Sleep Duration across the Adult Lifecourse and Risk of Lung Cancer Mortality: A Cohort Study in Xuanwei, China | 1.1 | 18 | Citations (PDF) |
| 69 | Kinetics of the Human Papillomavirus Type 16 E6 Antibody Response Prior to Oropharyngeal Cancer | 5.2 | 94 | Citations (PDF) |
| 70 | Flexible risk prediction models for left or interval-censored data from electronic health records | 1.2 | 19 | Citations (PDF) |
| 71 | Potential Impact of Including Time to First Cigarette in Risk Models for Selecting Ever-Smokers for Lung Cancer Screening | 1.1 | 16 | Citations (PDF) |
| 72 | Mixture models for undiagnosed prevalent disease and interval-censored incident disease: applications to a cohort assembled from electronic health records | 1.8 | 31 | Citations (PDF) |
| 73 | Proof-of-principle study of a novel cervical screening and triage strategy: Computer-analyzed cytology to decide which HPV-positive women are likely to have ≥CIN2 | 4.5 | 19 | Citations (PDF) |
| 74 | Response to Safiri et al. “Comments on Potential Impact of Including Time to First Cigarette in Risk Models for Selecting Ever-Smokers for Lung Cancer Screening” | 1.1 | 1 | Citations (PDF) |
| 75 | Applying Risk Prediction Models to Optimize Lung Cancer Screening: Current Knowledge, Challenges, and Future Directions | 3.4 | 16 | Citations (PDF) |
| 76 | 0303 Evaluating differences in expert agreement between subgroups to identify where to prioritise use of multiple raters 2017, , A93.3-A94 | | 0 | Citations (PDF) |
| 77 | Correlation of Leukocyte Telomere Length Measurement Methods in Patients with Dyskeratosis Congenita and in Their Unaffected Relatives | 4.5 | 43 | Citations (PDF) |
| 78 | Associations between self-reported diabetes and 78 circulating markers of inflammation, immunity, and metabolism among adults in the United States | 2.5 | 9 | Citations (PDF) |
| 79 | Reply to Letter: Using novel risk stratification statistics to better understand the value of screening tests | 4.5 | 0 | Citations (PDF) |
| 80 | Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening | 7.3 | 313 | Citations (PDF) |
| 81 | Effect of Recipient Age and Stem Cell Source on the Association between Donor Telomere Length and Survival after Allogeneic Unrelated Hematopoietic Cell Transplantation for Severe Aplastic Anemia | 1.8 | 26 | Citations (PDF) |
| 82 | Burden of HPV-positive oropharynx cancers among ever and never smokers in the U.S. population | 2.0 | 85 | Citations (PDF) |
| 83 | A risk-based framework to decide who benefits from screening | 70.2 | 17 | Citations (PDF) |
| 84 | Risk assessment to guide cervical screening strategies in a large <scp>C</scp>hinese population | 4.5 | 17 | Citations (PDF) |
| 85 | Cancer risk among the HIV-infected elderly in the United StatesAids, 2016, 30, 1663-1668 | 2.4 | 56 | Citations (PDF) |
| 86 | Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program | 0.9 | 14 | Citations (PDF) |
| 87 | Response | 5.2 | 0 | Citations (PDF) |
| 88 | Associations of Coffee Drinking with Systemic Immune and Inflammatory Markers | 0.9 | 69 | Citations (PDF) |
| 89 | A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results | 1.3 | 56 | Citations (PDF) |
| 90 | Leukoplakia, Oral Cavity Cancer Risk, and Cancer Survival in the U.S. Elderly | 1.1 | 39 | Citations (PDF) |
| 91 | Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica | 3.3 | 23 | Citations (PDF) |
| 92 | Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification | 5.2 | 88 | Citations (PDF) |
| 93 | Cigarette Smoking and Variations in Systemic Immune and Inflammation Markers | 5.2 | 302 | Citations (PDF) |
| 94 | A migrant study of pubertal timing and tempo in British-Bangladeshi girls at varying risk for breast cancer | 5.0 | 20 | Citations (PDF) |
| 95 | Reassurance Against Future Risk of Precancer and Cancer Conferred by a Negative Human Papillomavirus Test | 5.2 | 226 | Citations (PDF) |
| 96 | Tracking and Evaluating Molecular Tumor Markers With Cancer Registry Data: HER2 and Breast Cancer | 5.2 | 37 | Citations (PDF) |
| 97 | GBV-C Infection and Risk of NHL among U.S. Adults | 0.6 | 54 | Citations (PDF) |
| 98 | Tumor-Based Case–Control Studies of Infection and Cancer: Muddling the When and Where of Molecular Epidemiology | 0.9 | 3 | Citations (PDF) |
| 99 | Body Mass Index, Physical Activity, and Serum Markers of Inflammation, Immunity, and Insulin Resistance | 0.9 | 88 | Citations (PDF) |
| 100 | Childhood Environment Influences Adrenarcheal Timing among First-Generation Bangladeshi Migrant Girls to the UK | 2.5 | 28 | Citations (PDF) |
| 101 | Targeting of Low-Dose CT Screening According to the Risk of Lung-Cancer Death | 25.1 | 536 | Citations (PDF) |
| 102 | Circulating Inflammation Markers and Prospective Risk for Lung Cancer | 5.2 | 206 | Citations (PDF) |
| 103 | Selection Criteria for Lung-Cancer Screening | 25.1 | 902 | Citations (PDF) |
| 104 | Benchmarking CIN 3+ Risk as the Basis for Incorporating HPV and Pap Cotesting into Cervical Screening and Management Guidelines | 2.0 | 175 | Citations (PDF) |
| 105 | Five-Year Risks of CIN 2+ and CIN 3+ Among Women With HPV-Positive and HPV-Negative LSIL Pap Results | 2.0 | 54 | Citations (PDF) |
| 106 | Five-Year Risks of CIN 3+ and Cervical Cancer Among WomenWho Test Pap-Negative But Are HPV-Positive | 2.0 | 80 | Citations (PDF) |
| 107 | Five-Year Risk of Recurrence After Treatment of CIN 2, CIN 3, or AIS | 2.0 | 86 | Citations (PDF) |
| 108 | Follow-up Testing After Colposcopy | 2.0 | 64 | Citations (PDF) |
| 109 | Five-Year Risk of CIN 3+ to Guide the Management of Women Aged 21 to 24 Years | 2.0 | 32 | Citations (PDF) |
| 110 | Five-Year Risks of CIN 3+ and Cervical Cancer Among Women With HPV Testing of ASC-US Pap Results | 2.0 | 93 | Citations (PDF) |
| 111 | Five-Year Risks of CIN 3+ and Cervical Cancer Among Women With HPV-Positive and HPV-Negative High-Grade Pap Results | 2.0 | 64 | Citations (PDF) |
| 112 | 2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors | 1.5 | 677 | Citations (PDF) |
| 113 | How might HPV testing be integrated into cervical screening? | 11.2 | 15 | Citations (PDF) |
| 114 | Estimating the agreement and diagnostic accuracy of two diagnostic tests when one test is conducted on only a subsample of specimens | 1.8 | 25 | Citations (PDF) |
| 115 | Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice | 11.2 | 533 | Citations (PDF) |
| 116 | Effectiveness of VIA, Pap, and HPV DNA Testing in a Cervical Cancer Screening Program in a Peri-Urban Community in Andhra Pradesh, India | 2.5 | 115 | Citations (PDF) |
| 117 | Using DNA Fingerprints to Infer Familial Relationships Within NHANES III Households | 3.5 | 9 | Citations (PDF) |
| 118 | Risk estimation for the next generation of prevention programmes for cervical cancer | 11.2 | 44 | Citations (PDF) |
| 119 | Multiple diseases in carrier probability estimation: Accounting for surviving all cancers other than breast and ovary in BRCAPRO | 1.8 | 16 | Citations (PDF) |
| 120 | Hematologic and Biochemical Changes Associated with Human T Lymphotropic Virus Type 1 Infection in Jamaica: A Report from the Population-Based Blood Donors Study | 5.6 | 8 | Citations (PDF) |
| 121 | Breast-cancer risk in BRCA -mutation-negative women from BRCA -mutation-positive families | 11.2 | 13 | Citations (PDF) |
| 122 | Incorporating medical interventions into carrier probability estimation for genetic counseling | 2.0 | 18 | Citations (PDF) |
| 123 | Specifying and Implementing Nonparametric and Semiparametric Survival Estimators in Two-Stage (Nested) Cohort Studies With Missing Case Data | 3.5 | 31 | Citations (PDF) |
| 124 | Effect of Misreported Family History on Mendelian Mutation Prediction Models | 1.6 | 17 | Citations (PDF) |
| 125 | Assessing uncertainty in reference intervals via tolerance intervals: application to a mixed model describing HIV infection | 1.8 | 15 | Citations (PDF) |
| 126 | Title is missing! 2001, 7, 331-344 | | 17 | Citations (PDF) |
| 127 | Prospective Study of Serum Selenium Levels and Incident Esophageal and Gastric Cancers | 5.2 | 235 | Citations (PDF) |
